Biotin

Drug Profile

Biotin

Alternative Names: Coenzyme R; D-biotin; MD 1003; Vitamin H

Latest Information Update: 20 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MedDay Pharmaceuticals
  • Class Coenzymes; Imidazoles; Small molecules; Vitamins
  • Mechanism of Action Enzyme modulators; Enzyme stimulants; NF-kappa B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Multiple sclerosis
  • Phase II/III Adrenomyeloneuropathy
  • Phase II Amyotrophic lateral sclerosis
  • Phase I/II Charcot-Marie-Tooth disease; Chronic inflammatory demyelinating polyradiculoneuropathy
  • Preclinical Adrenoleucodystrophy

Most Recent Events

  • 01 Jun 2017 MedDay Pharmaceuticals completes the MD1003-AMN trial in Adrenomyeloneuropathy in Germany, France and Spain(PO) (NCT02961803) (EudraCT2014-000698-38)
  • 01 Nov 2016 Phase-III clinical trials in Multiple sclerosis in USA (PO) (NCT02936037)
  • 14 Sep 2016 Preclinical trials in Adrenoleucodystrophy in France before September 2016 (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top